ANL
Adlai Nortye (ANL)
$01
About Adlai Nortye (ANL)
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
Details
Daily high
$10.14
Daily low
$9.12
Price at open
$10.14
52 Week High
$12.09
52 Week Low
$0.88
Market cap
312.7M
Dividend yield
0.00%
Volume
414,448
Avg. volume
1.4M
P/E ratio
--
Adlai Nortye News
Details
Daily high
$10.14
Daily low
$9.12
Price at open
$10.14
52 Week High
$12.09
52 Week Low
$0.88
Market cap
312.7M
Dividend yield
0.00%
Volume
414,448
Avg. volume
1.4M
P/E ratio
--